Overview
Hubot, Inc. provides end-to-end formulation, development, and commercial-scale manufacturing of complex dosage forms, including aerosols, bag-on-valve systems, liquids, tubes, suppositories, and semi-solids for topical and oral applications. Its integrated South Bend facilities house R&D, analytical labs, and manufacturing to move products from concept to large-scale production, with operational support from its India subsidiary. The company differentiates itself through in-house, multi-vertical capabilities across development, quality systems (cGMP) and full regulatory compliance (ISO 9001, ISO 13485, ISO 22716) with FDA registration, serving Fortune 500 and emerging brands. Its goal is to bring complex, compliant products to market efficiently from concept through commercial-scale production.
Work here?Claim your company
Simplify's take
What believers are saying
- Hubot commissioned Line 35 on November 12, 2025, expanding roll-on and vial capacity.
- Redzone rollout on July 27, 2025 should lift uptime, traceability, and shop-floor discipline.
- Hubot's broad certifications—ISO 13485, ISO 22716, ISO 9001—win regulated brand mandates.
What critics are saying
- Micro Quality Labs sued Hubot in Delaware on March 30, 2026 over contracts.
- Forum-selection fights signal brittle purchasing terms and slower cash collection timelines.
- South Bend concentration creates existential shutdown risk from one fire, recall, or contamination event.
What makes Tri-Pac | Hubot unique
- South Bend integrates R&D, labs, and GMP manufacturing for OTC, devices, cosmetics.
- Hubot's 2025 roll-on line added automated filling for OTC, medical, and cosmetic runs.
- Hubot India in Mumbai supports back-office scaling while Indiana stays customer-facing.
Help us improve and share your feedback! Did you find this helpful?